Skip to main content

Table 3 Comparison of 2-year outcomes according to donor HLA matching, disease status, and use of in vivo T cell depletion

From: The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years—a report from the EBMT acute leukemia working party

Disease status

Patients group and p value

RI

NRM

LFS

OS

cGVHD

Extensive

cGVHD

All

10/10

30.1 % [28.2–32.1]

24.2 % [16.4–32.9]

45.6 % [43.5–47.7]

50.6 % [48.5–52.8]

35.0 % [32.9–37.2]

17.1 % [15.4–18.9]

 

9/10

32.5 % [28.9–36.3]

31.6 % [23–40.5]

35.8 % [32–39.7]

41.3 % [37.3–45.3]

35.1 % [31.2–39]

15.2 % [12.3–18.5]

 

8/10

24.2 % [16.4–32.9]

35.5 % [26.6–44.4]

40.3 % [30.6–50]

43.5 % [33.6–53.3]

44.4 % [33.6–54.6]

26.1 % [16.8–36.4]

 

p value

0.152

0.002

0.0001

0.0001

0.138

0.047

CR1

10/10

24.8 % [22.4–27.3]

22.5 % [11.6–35.7]

52.6 % [49.7–55.5]

56.7 % [53.8–59.6]

37.6 % [34.7–40.5]

18.1 % [15.8–20.5]

 

9/10

31.6 % [26.3–37.2]

26.8 % [14.8–40.2]

41.6 % [35.7–47.5]

46.1 % [40.1–52.2]

35.9 % [30–41.9]

13 % [9.1–17.7]

 

8/10

17.7 % [8.1–30.2]

33.3 % [20.4–46.8]

49% [34.3–63.7]

50.2 % % [35.2–65.1]

43.4 % [26.4–59.2]

22.1 % [9.5–37.9]

 

p value

0.010

0.136

0.005

0.005

0.641

0.107

≥CR2

10/10

32.6 % [28.2–37.1]

24.1 % [8.7–43.5]

43.3 % [38.5–48.1]

50.1 % [45.3–55]

35 % [30.3–39.7]

13.9 % [10.6–17.7]

 

9/10

26.3 % [19.5–33.5]

32.5 % [14.6–51.8]

41.2 % [33.3–49.2]

48 % [40–56.1]

34.7 % [26.8–42.7]

18.3 % [12.1–25.6]

 

8/10

22.4 % [7.7–41.7]

24.6 % [9.1–44.1]

53 % [31.3–74.7]

62 % [40.8–83.3]

65.5 % [39.6–82.4]

32.2 % [13.8–52.3]

 

p value

0.304

0.089

0.290

0.253

0.010

0.020

Act. dis.

10/10

39.7 % [35.7–43.7]

28 % [13.8–44]

32.3 % [28.4–36.3]

37.9 % [33.8–42]

29.4 % [25.5–33.4]

17.5 % [14–21.5]

 

9/10

38.4 % [31.6–45.3]

38 % [22.3–53.6]

23.6 % [17.4–29.7]

29.1 % [22.5–35.7]

33.9 % [27.1–40.8]

16.1 % [10.7–22.5]

 

8/10

34.3 % [19–50.2]

45.7 % [29.7–60.4]

20 % [6.7–33.3]

22.9 % [8.9–36.8]

30 % [14.4–47.4]

26.1 % [10.1–45.5]

 

p value

0.902

0.062

0.107

0.139

0.587

0.578

In vivo

No

28.8 % [25.4–32.3]

27.1 % [23.7–30.7]

44 % [40.1–48]

47.7 % [43.7–51.8]

45 % [40.8–49]

26.4 % [22.5–30.4]

T cell

Yes

30.7 % [28.8–32.6]

25.9 % [22.5–29.4]

43.4 % [41.3–45.5]

48.8 % [46.7–50.9]

32.9 % [30.9–34.9]

14.6 % [13–16.2]

Depletion

p value

0.920

0.448

0.613

0.448

1.0483e-05

1.337e-09

  1. Act. dis. active disease, cGVHD chronic graft-versus-host-disease, CR complete remission, LFS leukemia-free survival, NRM non relapse mortality, OS overall survival, RI relapse incidence